Provided by Tiger Trade Technology Pte. Ltd.

Silence Therapeutics Plc

13.29
+0.02000.15%
Post-market: 13.290.00000.00%19:33 EDT
Volume:723.69K
Turnover:9.67M
Market Cap:800.19M
PE:-10.47
High:13.59
Open:13.37
Low:13.05
Close:13.27
52wk High:17.58
52wk Low:4.19
Shares:60.21M
Float Shares:38.85M
Volume Ratio:0.75
T/O Rate:1.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2693
EPS(LYR):-1.8761
ROE:-90.41%
ROA:-29.65%
PB:20.80
PE(LYR):-7.08

Loading ...

European Equities Traded in the US as American Depositary Receipts Head Lower in Tuesday Trading

MT Newswires Live
·
Aug 18

Analysts Offer Insights on Healthcare Companies: Silence Therapeutics (SLN), Cardinal Health (CAH) and Allogene Therapeutics (ALLO)

TIPRANKS
·
Aug 17

Silence Therapeutics Closes Upsized $201.3 Million ADS Follow-on Offering at $13.5 Each

Reuters
·
Aug 15

European Equities Traded in the US Rise in Thursday Trading

MT Newswires Live
·
Aug 13

Silence Therapeutics 10% Owner Richard Ian Griffiths Disposes of ADS Worth $87.88 Million

Reuters
·
Aug 13

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Reuters
·
Aug 13

Silence Therapeutics Prices Upsized $175 Million ADS Offering at $13.5 Each

Reuters
·
Aug 12

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

MT Newswires Live
·
Aug 11

Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says

MT Newswires Live
·
Aug 11

Silence Therapeutics (SLN) Receives a Buy from Morgan Stanley

TIPRANKS
·
Aug 11

Silence Therapeutics Launches $150 Million ADS Follow-on Offering

Reuters
·
Aug 11

Top Midday Gainers

MT Newswires Live
·
Aug 11

Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO), Silence Therapeutics (SLN) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Aug 11

European Equities Traded in the US as American Depositary Receipts Edge Higher in Monday Trading

MT Newswires Live
·
Aug 10

Silence Therapeutics Shares up 32% After Q2 Results

THOMSON REUTERS
·
Aug 10

Silence Therapeutics Shares Climb on Blood-Cancer Trial Results

Dow Jones
·
Aug 10

Silence announces results from Phase 2 SANRECO trial met primary endpoint

TIPRANKS
·
Aug 10

Silence Therapeutics Says Phase 2 Sanreco Trial Meets Primary Endpoint for Divesiran in Polycythemia Vera

Reuters
·
Aug 10

Silence Therapeutics Q2 FY26 Net Loss Narrows to $12.3 Million; Revenue Falls to $0 from $224,000

Reuters
·
Aug 10

Press Release: Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

Dow Jones
·
Aug 10